Remy Klaassen1, Roelof J Bennink2, Geertjan van Tienhoven3, Maarten F Bijlsma4, Marc G H Besselink5, Mark I van Berge Henegouwen5, Johanna W Wilmink6, Aart J Nederveen7, Albert D Windhorst8, Maarten C C M Hulshof3, Hanneke W M van Laarhoven6. 1. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands; LEXOR (Laboratory for Experimental Oncology and Radiobiology), Academic Medical Center, Amsterdam, The Netherlands. Electronic address: r.klaassen@amc.uva.nl. 2. Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands. 3. Department of Radiation Oncology, Academic Medical Center, Amsterdam, The Netherlands. 4. LEXOR (Laboratory for Experimental Oncology and Radiobiology), Academic Medical Center, Amsterdam, The Netherlands. 5. Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. 6. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands. 7. Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands. 8. Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND AND PURPOSE: To investigate the feasibility and to determine the repeatability of recurrent [(18)F]HX4 PET scans in patients with oesophageal (EC) and pancreatic (PC) cancer. MATERIALS AND METHODS: 32 patients were scanned in total; seven patients (4 EC/3 PC) were scanned 2, 3 and 4h post injection (PI) of [(18)F]HX4 and 25 patients (15 EC/10 PC) were scanned twice 3.5h PI, on two separate days (median 4, range 1-9days). Maximum tumour to background ratio (TBRmax) and the tumour hypoxic volume (HV) (TBR>1.0) were calculated. Repeatability was assessed using Bland-Altman analysis. Agreement in localization was calculated as the distance between the centres of mass in the HVs. RESULTS: For EC, the TBRmax in the tumour (mean±SD) was 1.87±0.46 with a coefficient of repeatability (CoR) of 0.53 (28% of mean). The HV ranged from 3.4 to 98.8ml with a CoR of 5.1ml. For PC, the TBRmax was 1.72±0.23 with a CoR of 0.27 (16% of mean). The HV ranged from 4.6 to 104.0ml with a CoR of 7.8ml. The distance between the centres of mass in the HV was 2.2±1.3mm for EC and 2.1±1.5mm for PC. CONCLUSIONS: PET scanning with [(18)F]HX4 was feasible in both EC and PC patients. Amount and location of elevated [(18)F]HX4 uptake showed good repeatability, suggesting [(18)F]HX4 PET could be a promising tool for radiation therapy planning and treatment response monitoring in EC and PC patients.
BACKGROUND AND PURPOSE: To investigate the feasibility and to determine the repeatability of recurrent [(18)F]HX4 PET scans in patients with oesophageal (EC) and pancreatic (PC) cancer. MATERIALS AND METHODS: 32 patients were scanned in total; seven patients (4 EC/3 PC) were scanned 2, 3 and 4h post injection (PI) of [(18)F]HX4 and 25 patients (15 EC/10 PC) were scanned twice 3.5h PI, on two separate days (median 4, range 1-9days). Maximum tumour to background ratio (TBRmax) and the tumour hypoxic volume (HV) (TBR>1.0) were calculated. Repeatability was assessed using Bland-Altman analysis. Agreement in localization was calculated as the distance between the centres of mass in the HVs. RESULTS: For EC, the TBRmax in the tumour (mean±SD) was 1.87±0.46 with a coefficient of repeatability (CoR) of 0.53 (28% of mean). The HV ranged from 3.4 to 98.8ml with a CoR of 5.1ml. For PC, the TBRmax was 1.72±0.23 with a CoR of 0.27 (16% of mean). The HV ranged from 4.6 to 104.0ml with a CoR of 7.8ml. The distance between the centres of mass in the HV was 2.2±1.3mm for EC and 2.1±1.5mm for PC. CONCLUSIONS: PET scanning with [(18)F]HX4 was feasible in both EC and PC patients. Amount and location of elevated [(18)F]HX4 uptake showed good repeatability, suggesting [(18)F]HX4 PET could be a promising tool for radiation therapy planning and treatment response monitoring in EC and PC patients.
Authors: Emily Chan; Lori R Arlinghaus; Dana B Cardin; Laura Goff; Jordan D Berlin; Alexander Parikh; Richard G Abramson; Thomas E Yankeelov; Scott Hiebert; Nipun Merchant; Srividya Bhaskara; Anuradha Bapsi Chakravarthy Journal: Radiother Oncol Date: 2016-04-19 Impact factor: 6.280
Authors: Ruben T H M Larue; Lien Van De Voorde; Maaike Berbée; Wouter J C van Elmpt; Ludwig J Dubois; Kranthi M Panth; Sarah G J A Peeters; Ann Claessens; Wendy M J Schreurs; Marius Nap; Fabiënne A R M Warmerdam; Frans L G Erdkamp; Meindert N Sosef; Philippe Lambin Journal: BMC Cancer Date: 2016-08-17 Impact factor: 4.430
Authors: Katarzyna B Leszczynska; Greg Dobrynin; Rhea E Leslie; Jonathan Ient; Adam J Boumelha; Joana M Senra; Maria A Hawkins; Tim Maughan; Somnath Mukherjee; Ester M Hammond Journal: Radiother Oncol Date: 2016-11-10 Impact factor: 6.280
Authors: Milan Grkovski; Louise Fanchon; Naga Vara Kishore Pillarsetty; James Russell; John L Humm Journal: EJNMMI Res Date: 2018-06-18 Impact factor: 3.138
Authors: Wouter van Elmpt; Catharina M L Zegers; Bart Reymen; Aniek J G Even; Anne-Marie C Dingemans; Michel Oellers; Joachim E Wildberger; Felix M Mottaghy; Marco Das; Esther G C Troost; Philippe Lambin Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-04 Impact factor: 9.236